Sarah E. Fowler

TL;DR: In this paper, the authors compared a lifestyle intervention with metformin to prevent or delay the development of Type 2 diabetes in nondiabetic individuals. And they found that the lifestyle intervention was significantly more effective than the medication.

TL;DR: During follow-up after DPP, incidences in the former placebo and metformin groups fell to equal those in theFormer lifestyle group, but the cumulative incidence of diabetes remained lowest in the lifestyle group.

TL;DR: In patients with suspected pulmonary embolism, multidetector CTA-CTV has a higher diagnostic sensitivity than does CTA alone, with similar specificity, and additional testing is necessary when the clinical probability is inconsistent with the imaging results.

TL;DR: In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization.

TL;DR: In this paper, the authors used lifestyle intervention and metformin therapy to reduce the incidence of metabolic syndrome in the participants of the Diabetes Prevention Program. But, only half of the participants had the metabolic syndrome.